Login / Register The Most Trusted Name in Medical Education


Improve your knowledge in the field of urology by taking one of Elsevier's complimentary continuing medical education courses.

138 17 287 JS 140x117

Immunotherapy: The Wave of the Future in Bladder Cancer?

Format: Supplement

This article reviews the role of immunotherapy in the treatment of locally advanced and metastatic urothelial cell carcinoma (UC). It describes the basic principles of cancer immunotherapy, as they relate to management of UC, and summarizes clinical data on current and investigational therapeutic approaches. Two immune checkpoint inhibitors are now approved for treatment of advanced UC in the United States, and the article discusses their unique response patterns and side effect profiles to help oncology clinicians appropriately incorporate these agents into patient care.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910750 116 x 140

ESMO 2017: A Therapeutic Update on the Management of Patients with Metastatic Renal Cell Carcinoma

Format: Medical Meeting Reporter

This webcast on metastatic renal cell carcinoma (mRCC) is based on a roundtable discussion among three key opinion leaders in the field. The experts will present updates on the management of mRCC and summarize and discuss the latest clinical trial data presented during the ESMO 2017 Congress, held in Madrid, Spain, on September 8–12, 2017. Advances in the use of targeted therapies such as VEGFR inhibitors, novel immunotherapies, and combination therapies including PD-1/PD-L1 and CTLA4 targeting agents will be examined. The experts will address the question of how novel treatment options could be included in individualized treatment plans when approved, to optimize treatment selection and outcomes for patients with mRCC.

Take Course »


Credits: 1.0 AMA PRA Category 1 Credit™
910692 116 x 140

ASCO GU 2017: A Therapeutic Update on the Management of Patients with Prostate Cancer

Format: Conference Reporter

Ground-breaking research on the molecular and genetic properties of prostate cancer (PC) was presented at the 2017 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO), held on February 16–18 in Orlando, Florida. This research provided many insights on the genetic changes associated with disease progression and the development of treatment resistance that may help inform treatment decisions for patients with PC in the near future. In this video presentation, three leading experts in the management of PC review key results presented at ASCO-GU 2017 and provide their thoughts on how the results may influence current research and practice.

Take Course »


Credits: 1.00 AMA PRA Category 1 Credit(s)™